{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T07:55:03Z","timestamp":1794470103351,"version":"4.9.1"},"reference-count":79,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>SUMMARY<\/jats:title>\n                  <jats:p>With an estimated 3.8 million breast cancer survivors in the United States, obstetrician\u2013gynecologists often are on the front lines of addressing survivorship issues, including the hypoestrogenic-related adverse effects of cancer therapies or early menopause in survivors (1). Although systemic and vaginal estrogen are used widely for symptomatic relief of genitourinary syndrome of menopause in the general population, among individuals with a history of hormone-sensitive cancer, there is uncertainty about the safety of hormone-based therapy, leading many individuals with bothersome symptoms to remain untreated, with potential negative consequences on quality of life (2). An effective management strategy requires familiarity with a range of both hormonal and nonhormonal treatment options, knowledge about the pharmaceutical mechanisms of action, and the ability to tailor treatment based on individual risk factors. This clinical consensus document was developed using an a priori protocol in conjunction with two authors specializing in urogynecology and gynecologic oncology. This document has been updated to review the safety and efficacy of newer hormonal treatment options as well as nonhormonal modalities.<\/jats:p>","DOI":"10.1097\/aog.0000000000004601","type":"journal-article","created":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T17:04:29Z","timestamp":1637255069000},"page":"950-960","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":69,"title":["ACOG Clinical Consensus No. 2: Treatment of Urogenital Symptoms in Individuals with a History of Estrogen-dependent Breast Cancer"],"prefix":"10.1097","volume":"138","author":[{"name":"American College of Obstetricians and Gynecologists\u2019 Committee on Clinical Consensus \u2013 Gynecology","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260916","first-page":"363","article-title":"Cancer treatment and survivorship statistics, 2019","volume":"69","author":"Miller","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"R2-20260916","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/GME.0000000000001260","article-title":"The burden of vulvovaginal atrophy on women's daily living: implications on quality of life from a face-to-face real-life survey. EVES Study investigators","volume":"26","author":"Nappi","year":"2019","journal-title":"Menopause"},{"key":"R3-20260916","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1111\/jsm.12686","article-title":"Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society. Vulvovaginal Atrophy Terminology Consensus Conference Panel","volume":"11","author":"Portman","year":"2014","journal-title":"J Sex Med"},{"key":"R4-20260916","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"R6-20260916","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1001\/jamasurg.2018.0035","article-title":"Race\/ethnicity and age distribution of breast cancer diagnosis in the United States","volume":"153","author":"Stapleton","year":"2018","journal-title":"JAMA Surg"},{"key":"R7-20260916","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s10549-011-1762-1","article-title":"Racial\/ethnic differences in initiation of adjuvant hormonal therapy among women with hormone receptor-positive breast cancer","volume":"131","author":"Livaudais","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"R8-20260916","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s10549-013-2499-9","article-title":"Adjuvant endocrine therapy initiation and persistence in a diverse sample of patients with breast cancer","volume":"138","author":"Friese","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"R9-20260916","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1080\/14737140.2018.1520096","article-title":"Managing side effects in adjuvant endocrine therapy for breast cancer","volume":"18","author":"Condorelli","year":"2018","journal-title":"Expert Rev Anticancer Ther"},{"key":"R10-20260916","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/AOG.0000000000004520","article-title":"Clinical consensus methodology","volume":"138","year":"2021","journal-title":"Obstet Gynecol"},{"issue":"suppl 1","key":"R12-20260916","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.3747\/co.2007.151","article-title":"Management of sexual dysfunction in postmenopausal breast cancer patients taking adjuvant aromatase inhibitor therapy","volume":"14","author":"Derzko","year":"2007","journal-title":"Curr Oncol"},{"key":"R13-20260916","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1200\/JOP.18.00710","article-title":"Managing genitourinary syndrome of menopause in breast cancer survivors receiving endocrine therapy","volume":"15","author":"Sussman","year":"2019","journal-title":"J Oncol Pract"},{"key":"R14-20260916","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1097\/AOG.0000000000001988","article-title":"Effect of a pH-balanced vaginal gel on dyspareunia and sexual function in breast cancer survivors who were premenopausal at diagnosis: a randomized controlled trial","volume":"129","author":"Kim","year":"2017","journal-title":"Obstet Gynecol"},{"key":"R15-20260916","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1097\/AOG.0b013e3182118790","article-title":"Vaginal pH-balanced gel for the control of atrophic vaginitis among breast cancer survivors: a randomized controlled trial","volume":"117","author":"Lee","year":"2011","journal-title":"Obstet Gynecol"},{"key":"R16-20260916","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40695-015-0009-4","article-title":"Management of sexual dysfunction in breast cancer survivors: a systematic review","volume":"1","author":"Seav","year":"2015","journal-title":"Womens Midlife Health"},{"key":"R17-20260916","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3109\/13697137.2012.756466","article-title":"Non-hormonal topical treatment of vulvovaginal atrophy: an up-to-date overview","volume":"16","author":"Sinha","year":"2013","journal-title":"Climacteric"},{"key":"R18-20260916","doi-asserted-by":"crossref","first-page":"e0210967","DOI":"10.1371\/journal.pone.0210967","article-title":"Topical treatment of vaginal dryness with a non-hormonal cream in women undergoing breast cancer treatment - an open prospective multicenter study","volume":"14","author":"Chatsiproios","year":"2019","journal-title":"PLoS One"},{"key":"R19-20260916","doi-asserted-by":"crossref","first-page":"404","DOI":"10.3109\/09513591003632258","article-title":"Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study","volume":"26","author":"Biglia","year":"2010","journal-title":"Gynecol Endocrinol"},{"key":"R20-20260916","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1200\/JCO.1997.15.3.969","article-title":"Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer","volume":"15","author":"Loprinzi","year":"1997","journal-title":"J Clin Oncol"},{"key":"R21-20260916","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s10549-016-3865-1","article-title":"A randomized, double-blind, crossover trial comparing a silicone- versus water-based lubricant for sexual discomfort after breast cancer","volume":"158","author":"Hickey","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"R22-20260916","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1080\/13697137.2016.1258396","article-title":"Can polyacrylic acid treat sexual dysfunction in women with breast cancer receiving tamoxifen?","volume":"20","author":"Juliato","year":"2017","journal-title":"Climacteric"},{"issue":"suppl 1","key":"R23-20260916","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/jsm.12034","article-title":"Sexual health issues in women with cancer","volume":"10","author":"Krychman","year":"2013","journal-title":"J Sex Med"},{"key":"R24-20260916","first-page":"1325","article-title":"The effect of vitamin D and E vaginal suppositories on tamoxifen-induced vaginal atrophy in women with breast cancer","volume":"27","author":"Keshavarzi","year":"2019","journal-title":"Support Care Cancer"},{"key":"R25-20260916","first-page":"311","article-title":"A single-arm, prospective trial investigating the effectiveness of a non-hormonal vaginal moisturizer containing hyaluronic acid in postmenopausal cancer survivors","volume":"29","author":"Carter","year":"2021","journal-title":"Support Care Cancer"},{"key":"R26-20260916","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1097\/GME.0000000000001609","article-title":"The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society","volume":"27","year":"2020","journal-title":"Menopause"},{"key":"R27-20260916","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1200\/JCO.2014.60.7366","article-title":"A practical solution for dyspareunia in breast cancer survivors: a randomized controlled trial","volume":"33","author":"Goetsch","year":"2015","journal-title":"J Clin Oncol"},{"key":"R28-20260916","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1097\/AOG.0000000000000283","article-title":"Locating pain in breast cancer survivors experiencing dyspareunia: a randomized controlled trial","volume":"123","author":"Goetsch","year":"2014","journal-title":"Obstet Gynecol"},{"key":"R29-20260916","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1111\/jsm.12156","article-title":"The acceptability, feasibility, and efficacy (phase I\/II study) of the OVERcome (Olive Oil, Vaginal Exercise, and MoisturizeR) intervention to improve dyspareunia and alleviate sexual problems in women with breast cancer","volume":"10","author":"Juraskova","year":"2013","journal-title":"J Sex Med"},{"key":"R30-20260916","doi-asserted-by":"crossref","first-page":"e12678","DOI":"10.1111\/dth.12678","article-title":"Primavera: a new therapeutical approach to vulvo-vaginal atrophy","volume":"31","author":"Amori","year":"2018","journal-title":"Dermatol Ther"},{"key":"R31-20260916","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1097\/GME.0000000000000316","article-title":"Why the product labeling for low-dose vaginal estrogen should be changed. Working Group on Women\u2019s Health and Well-Being in Menopause","volume":"21","author":"Manson","year":"2014","journal-title":"Menopause"},{"key":"R32-20260916","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(19)31709-X","article-title":"Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Collaborative Group on Hormonal Factors in Breast Cancer","volume":"394","year":"2019","journal-title":"Lancet"},{"key":"R33-20260916","first-page":"322","article-title":"Hormone replacement therapy: an increased risk of recurrence and mortality for breast cancer patients?","volume":"6","author":"Lupo","year":"2015","journal-title":"J Adv Pract Oncol"},{"key":"R34-20260916","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ajog.2019.08.043","article-title":"Management of genitourinary syndrome of menopause in female cancer patients: a focus on vaginal hormonal therapy","volume":"222","author":"Crean-Tate","year":"2020","journal-title":"Am J Obstet Gynecol"},{"key":"R35-20260916","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1001\/jamaoncol.2016.3904","article-title":"Vaginal testosterone cream vs estradiol vaginal ring for vaginal dryness or decreased libido in women receiving aromatase inhibitors for early-stage breast cancer: a randomized clinical trial [published erratum appears in JAMA Oncol 2020;6:1473]","volume":"3","author":"Melisko","year":"2017","journal-title":"JAMA Oncol"},{"key":"R36-20260916","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/01.GME.0000061806.76067.E9","article-title":"Estrogen replacement therapy in breast cancer survivors: a matched-controlled series","volume":"10","author":"Decker","year":"2003","journal-title":"Menopause"},{"key":"R37-20260916","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1093\/annonc\/mdj127","article-title":"Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors","volume":"17","author":"Kendall","year":"2006","journal-title":"Ann Oncol"},{"key":"R38-20260916","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3109\/13697137.2010.529967","article-title":"Vaginal estriol to overcome side-effects of aromatase inhibitors in breast cancer patients","volume":"14","author":"Pfeiler","year":"2011","journal-title":"Climacteric"},{"key":"R39-20260916","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3109\/13697137.2014.991301","article-title":"Vaginal estriol-lactobacilli combination and quality of life in endocrine-treated breast cancer","volume":"18","author":"Buchholz","year":"2015","journal-title":"Climacteric"},{"key":"R40-20260916","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s10549-014-2930-x","article-title":"Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor(\u00ae)) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study","volume":"145","author":"Donders","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"R41-20260916","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/GME.0000000000001497","article-title":"Efficacy and safety of ultra-low dose 0.005% estriol vaginal gel for the treatment of vulvovaginal atrophy in postmenopausal women with early breast cancer treated with nonsteroidal aromatase inhibitors: a phase II, randomized, double-blind, placebo-controlled trial","volume":"27","author":"Hirschberg","year":"2020","journal-title":"Menopause"},{"key":"R42-20260916","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10549-015-3434-z","article-title":"Management of urogenital atrophy in breast cancer patients: a systematic review of available evidence from randomized trials","volume":"152","author":"Mazzarello","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"R43-20260916","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1007\/s10096-015-2447-1","article-title":"Effect of ultra-low-dose estriol and lactobacilli vaginal tablets (Gynoflor\u00ae) on inflammatory and infectious markers of the vaginal ecosystem in postmenopausal women with breast cancer on aromatase inhibitors","volume":"34","author":"Donders","year":"2015","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"R44-20260916","doi-asserted-by":"crossref","first-page":"e731","DOI":"10.1016\/j.clbc.2019.07.007","article-title":"The safety of local hormonal treatment for vulvovaginal atrophy in women with estrogen receptor-positive breast cancer who are on adjuvant aromatase inhibitor therapy: meta-analysis","volume":"19","author":"Pavlovi\u0107","year":"2019","journal-title":"Clin Breast Cancer"},{"key":"R45-20260916","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/GME.0000000000001447","article-title":"Hormonal management of menopausal symptoms in women with a history of gynecologic malignancy","volume":"27","author":"Harris","year":"2020","journal-title":"Menopause"},{"key":"R46-20260916","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1200\/JOP.2011.000352","article-title":"Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator","volume":"8","author":"Wills","year":"2012","journal-title":"J Oncol Pract"},{"key":"R47-20260916","first-page":"187","article-title":"Changes in serum estradiol levels with Estring in postmenopausal women with breast cancer treated with aromatase inhibitors","volume":"29","author":"Streff","year":"2021","journal-title":"Support Care Cancer"},{"key":"R48-20260916","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/cmt.6.1.45.52","article-title":"A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer","volume":"6","author":"Dew","year":"2003","journal-title":"Climacteric"},{"key":"R49-20260916","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10549-012-2198-y","article-title":"Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case-control study","volume":"135","author":"Le Ray","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"R50-20260916","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1097\/01.AOG.0000241091.86268.6e","article-title":"Breast cancer risk in postmenopausal women using estrogen-only therapy","volume":"108","author":"Lyytinen","year":"2006","journal-title":"Obstet Gynecol"},{"key":"R51-20260916","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/GME.0000000000000956","article-title":"Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women's Health Initiative Observational Study","volume":"25","author":"Crandall","year":"2018","journal-title":"Menopause"},{"key":"R52-20260916","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/jnci\/93.10.754","article-title":"Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality","volume":"93","author":"O'Meara","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"R53-20260916","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1097\/GME.0000000000001079","article-title":"Vaginal estrogen and mammogram results: case series and review of literature on treatment of genitourinary syndrome of menopause (GSM) in breast cancer survivors","volume":"25","author":"Zuo","year":"2018","journal-title":"Menopause"},{"key":"R55-20260916","first-page":"643","article-title":"Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance)","volume":"26","author":"Barton","year":"2018","journal-title":"Support Care Cancer"},{"key":"R56-20260916","first-page":"1335","article-title":"Systemic and local effects of vaginal dehydroepiandrosterone (DHEA): NCCTG N10C1 (Alliance)","volume":"26","author":"Barton","year":"2018","journal-title":"Support Care Cancer"},{"key":"R57-20260916","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/GME.0000000000001052","article-title":"A systematic review of intravaginal testosterone for the treatment of vulvovaginal atrophy","volume":"25","author":"Bell","year":"2018","journal-title":"Menopause"},{"key":"R58-20260916","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1188\/17.ONF.296-301","article-title":"Vaginal testosterone for management of aromatase inhibitor-related sexual dysfunction: an integrative review","volume":"44","author":"Lemke","year":"2017","journal-title":"Oncol Nurs Forum"},{"key":"R59-20260916","doi-asserted-by":"crossref","first-page":"4146","DOI":"10.1210\/jc.2018-01345","article-title":"Intravaginal testosterone improves sexual satisfaction and vaginal symptoms associated with aromatase inhibitors","volume":"103","author":"Davis","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"R60-20260916","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/sm2.22","article-title":"Breast cancer, aromatase inhibitor therapy, and sexual functioning: a pilot study of the effects of vaginal testosterone therapy","volume":"2","author":"Dahir","year":"2014","journal-title":"Sex Med"},{"key":"R61-20260916","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1111\/j.1743-6109.2007.00577.x","article-title":"A case series of androgen use in breast cancer survivors with sexual dysfunction","volume":"4","author":"Krychman","year":"2007","journal-title":"J Sex Med"},{"key":"R62-20260916","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1634\/theoncologist.2010-0435","article-title":"Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I\/II study","volume":"16","author":"Witherby","year":"2011","journal-title":"Oncologist"},{"key":"R63-20260916","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.maturitas.2018.11.017","article-title":"Ospemifene for the treatment of vulvar and vaginal atrophy: a meta-analysis of randomized trials. Part II: evaluation of tolerability and safety","volume":"121","author":"Di Donato","year":"2019","journal-title":"Maturitas"},{"key":"R64-20260916","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/GME.0000000000001292","article-title":"Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial","volume":"26","author":"Archer","year":"2019","journal-title":"Menopause"},{"key":"R68-20260916","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.maturitas.2020.06.021","article-title":"No increase in incidence or risk of recurrence of breast cancer in ospemifene-treated patients with vulvovaginal atrophy (VVA)","volume":"142","author":"Cai","year":"2020","journal-title":"Maturitas"},{"key":"R69-20260916","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2147\/PPA.S203614","article-title":"Ospemifene in the management of vulvar and vaginal atrophy: focus on the assessment of patient acceptability and ease of use","volume":"14","author":"Cagnacci","year":"2020","journal-title":"Patient Prefer Adherence"},{"key":"R70-20260916","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1111\/jsm.12428","article-title":"Assessment of ospemifene or lubricants on clinical signs of VVA","volume":"11","author":"Constantine","year":"2014","journal-title":"J Sex Med"},{"key":"R71-20260916","doi-asserted-by":"crossref","first-page":"e556","DOI":"10.1016\/j.clbc.2019.04.007","article-title":"The impact of vaginal laser treatment for genitourinary syndrome of menopause in breast cancer survivors: a systematic review and meta-analysis","volume":"19","author":"Jha","year":"2019","journal-title":"Clin Breast Cancer"},{"key":"R72-20260916","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10103-019-02855-9","article-title":"Intravaginal energy-based devices and sexual health of female cancer survivors: a systematic review and meta-analysis","volume":"35","author":"Athanasiou","year":"2020","journal-title":"Lasers Med Sci"},{"key":"R73-20260916","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1097\/GME.0000000000001353","article-title":"The effect of vaginal erbium laser treatment on sexual function and vaginal health in women with a history of breast cancer and symptoms of the genitourinary syndrome of menopause: a prospective study","volume":"26","author":"Ar\u00eaas","year":"2019","journal-title":"Menopause"},{"key":"R74-20260916","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s00432-018-2614-8","article-title":"Ablative dual-phase Erbium:YAG laser treatment of atrophy-related vaginal symptoms in post-menopausal breast cancer survivors omitting hormonal treatment","volume":"144","author":"Mothes","year":"2018","journal-title":"J Cancer Res Clin Oncol"},{"key":"R75-20260916","doi-asserted-by":"crossref","DOI":"10.1016\/j.clbc.2021.01.006","article-title":"Microablative fractional CO2 laser for vulvovaginal atrophy in women with a history of breast cancer: a pilot study at 4-week follow-up","author":"Salvatore","year":"2021","journal-title":"Clin Breast Cancer"},{"key":"R76-20260916","first-page":"N.1","article-title":"Vaginal erbium laser: the second generation thermotherapy for the genitourinary syndrome of menopause (GSM) in breast cancer survivors. A preliminary report of a pilot study","volume":"27","author":"Gambacciani","year":"2015","journal-title":"It J Gynaecol Obstet"},{"key":"R77-20260916","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/GME.0000000000000761","article-title":"Vaginal erbium laser as second-generation thermotherapy for the genitourinary syndrome of menopause: a pilot study in breast cancer survivors","volume":"24","author":"Gambacciani","year":"2017","journal-title":"Menopause"},{"key":"R78-20260916","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1097\/GME.0000000000000672","article-title":"Fractional microablative CO2 laser for vulvovaginal atrophy in women treated with chemotherapy and\/or hormonal therapy for breast cancer: a retrospective study","volume":"23","author":"Pagano","year":"2016","journal-title":"Menopause"},{"key":"R79-20260916","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/GME.0000000000001053","article-title":"Fractional microablative CO2 laser in breast cancer survivors affected by iatrogenic vulvovaginal atrophy after failure of nonestrogenic local treatments: a retrospective study [published erratum appears in Menopause 2018;25:1169]","volume":"25","author":"Pagano","year":"2018","journal-title":"Menopause"},{"key":"R80-20260916","first-page":"3669","article-title":"Fractional CO2 laser therapy for genitourinary syndrome of menopause for breast cancer survivors","volume":"28","author":"Quick","year":"2020","journal-title":"Support Care Cancer"},{"key":"R81-20260916","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/14764172.2018.1481510","article-title":"The effects of fractional microablative CO2 laser therapy on sexual function in postmenopausal women and women with a history of breast cancer treated with endocrine therapy","volume":"21","author":"Gittens","year":"2019","journal-title":"J Cosmet Laser Ther"},{"key":"R82-20260916","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s00404-016-4118-6","article-title":"Fractional CO2 laser for vulvovaginal atrophy (VVA) dyspareunia relief in breast cancer survivors","volume":"294","author":"Pieralli","year":"2016","journal-title":"Arch Gynecol Obstet"},{"key":"R83-20260916","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1097\/GME.0000000000001738","article-title":"Patient-reported sexual function of breast cancer survivors with genitourinary syndrome of menopause after fractional CO2 laser therapy","volume":"28","author":"Quick","year":"2021","journal-title":"Menopause"},{"key":"R84-20260916","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s10549-021-06226-3","article-title":"Effects of local laser treatment on vulvovaginal atrophy among women with breast cancer: a prospective study with long-term follow-up","volume":"188","author":"Veron","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"R85-20260916","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1080\/14656566.2019.1574752","article-title":"Pharmacotherapy for the treatment of vaginal atrophy","volume":"20","author":"Donders","year":"2019","journal-title":"Expert Opin Pharmacother"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000004601","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:01:14Z","timestamp":1789556474000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000004601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":79,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000004601","relation":{},"ISSN":["0029-7844","1873-233X"],"issn-type":[{"value":"0029-7844","type":"print"},{"value":"1873-233X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"2021-09-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}}]}}